Sarepta Therapeutics Newsroom

Sarepta Therapeutics to Present New Data From Its Neuromuscular Portfolio at 2024 World Muscle Society Congress

BusinesswireSep 26 20:30

Sarepta Therapeutics Price Target Maintained With a $152.00/Share by Cantor Fitzgerald

Dow JonesSep 20 22:17 · Ratings

Cantor Fitzgerald Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $152

Cantor Fitzgerald analyst Kristen Kluska maintains $Sarepta Therapeutics(SRPT.US)$ with a hold rating, and maintains the target price at $152.According to TipRanks data, the analyst has a success

Futu NewsSep 20 20:31 · Ratings

Cantor Fitzgerald Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

TipRanksSep 20 19:45 · Ratings

Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options

Zacks Sep 19 19:35

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaSep 19 01:35

Express News | Sarepta Therapeutics Inc - Board Now Comprises Nine Directors, Eight Independent

BreakingsSep 16 20:31

Sarepta Therapeutics Appoints Deirdre Connelly to Its Board of Directors

BusinesswireSep 16 20:30

High Growth Tech Stocks In The United States You Should Know

Yahoo FinanceSep 13 18:02

BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

BMO Capital analyst Kostas Biliouris maintains $Sarepta Therapeutics(SRPT.US)$ with a buy rating, and maintains the target price at $200.According to TipRanks data, the analyst has a success rate of 4

Futu NewsSep 12 03:32 · Ratings

Sarepta Therapeutics on Track for Longest Losing Streak Since September 2019 -- Data Talk

Dow JonesSep 10 22:47

TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203

TD Cowen analyst Ritu Baral maintains $Sarepta Therapeutics(SRPT.US)$ with a buy rating, and maintains the target price at $203.According to TipRanks data, the analyst has a success rate of 45.1%

Futu NewsSep 9 19:31 · Ratings

Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen

TipRanksSep 9 19:15 · Ratings

Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar

Yahoo FinanceSep 8 14:00

Unveiling 26 Analyst Insights On Sarepta Therapeutics

BenzingaSep 7 01:01

RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target

BenzingaSep 6 20:47 · Ratings

Sarepta Therapeutics Analyst Ratings

BenzingaSep 6 20:46 · Ratings

RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181

RBC Capital analyst Brian Abrahams maintains $Sarepta Therapeutics(SRPT.US)$ with a buy rating, and maintains the target price at $181.According to TipRanks data, the analyst has a success rate of 48.

Futu NewsSep 6 19:33 · Ratings

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Danaher (DHR)

TipRanksSep 6 18:40 · Ratings

Russell Companies With the Lowest Tax Rates Expected to Generate $1B in 2025 – GS

Seeking AlphaSep 5 23:08